On Aug. 4, 2025, The Gates Foundation announced a $2.5 billion commitment through 2030 to accelerate research and development (R&D) focused exclusively on women’s health. It will support the advancement of more than 40 innovations in five critical, chronically underfunded areas—particularly those affecting women in low- and middle-income countries.

“For too long, women have suffered from health conditions that are misunderstood, misdiagnosed, or ignored,” said Dr. Anita Zaidi, president of the Gates Foundation’s Gender Equality Division. “We want this investment to spark a new era of women-centered innovation—one where women’s lives, bodies, and voices are prioritized in health R&D.”

Women’s health R&D remains chronically underfunded. Areas such as gynecological and menstrual health, obstetric care, contraceptive innovation, sexually transmitted infections (STIs) solutions (including HIV PrEP for women), and maternal health and nutrition receive limited investment. According to a 2021 analysis, led by McKinsey & Company, just 1% of healthcare research and innovation is invested in female-specific conditions beyond oncology. Critical issues like preeclampsia, gestational diabetes, heavy menstrual bleeding, endometriosis, and menopause, which together affect hundreds of million women, remain deeply under-researched.

To close persistent gaps in funding and research, the foundation is urging governments, philanthropists, investors, and the private sector to co-invest in women’s health innovations, help shape product development, and ensure access to treatments for the women and girls who need them most.

By addressing long-standing gaps in women’s health, the investment aims to unlock broader social and economic gains. Research shows that every $1 invested in women’s health yields $3 in economic growth, and closing the gender health gap could boost the global economy by $1 trillion per year by 2040.